Professor Kwee Yong : Haematology

Home
Professor Kwee Yong

Not Fee assured
Awaiting verification
Open Referral network

Overview

Specialises in

Haemato-oncology

About me

Specialist in multiple myeloma, chief investigator running early phase NCRN clinical trials in myeloma

Areas of interest

Myeloma; Plasma cell disorders

Medical secretaries

Teresa Macdonald
5th Floor University College Hospital Macmillan Cancer Centre Huntley Street LONDON WC1E 6AG
020 7679 6221
020 7679 6222
t.macdonald@ucl.ac.uk

About me

Current NHS consultant posts held

University College London Hospitals

Research interests

Biology and bone disease in multiple myeloma, exploring new agents and novel strategies in early phase clinical studies

Publications

1. Groeneveldt L, Mein G, Garrod R, Jewell AP, Someren K, Stephens R, D Sa SP, Yong KL. (2013) A Mixed Exercise Training Programme Is Feasible and Safe and May Improve Quality of Life and Muscle Strength in Multiple Myeloma Survivors.” BMC Cancer 13, no. 1 (January 24, 2013): 31. doi:10.1186/1471-2407-13-31.
2. Rabin N, Percy L, Khan I, Quinn J, D’Sa S, Yong KL (2012) Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. Br J Haematol 2012 June 19 (epub)
3. Percy LA, Moore SE, Qian W, Dorman J, Rabin N, Watts M, Linch DC, Yong KL. (2012) Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma. Br J Haematol; 157:1365
4. Stengel C, Cheung CW, Quinn J, Yong K, Khwaja A. Optimal Induction of Myeloma Cell Death Requires Dual Blockade of Phosphoinositide 3-kinase and mTOR Signalling and Is Determined by Translocation Subtype. Leukemia epub (March 14, 2012). http://www.ncbi.nlm.nih.gov/pubmed/22415553.
5. Glassford J, Kassen D, Quinn J, Stengel C, Kallinikou K, Khwaja A, Yong KL (2012). Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations. Blood Cancer J 2012 Jan;2(1):e50. Epub 2012 Jan 13.
6. Quinn, J., Glassford, J., Percy, L., Munson, P., Marafioti, T., Rodriguez-justo, M., Yong, K. (2011). APRIL promotes cell cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood 117:890-901

My qualifications & training

Qualifications

MA Oxon 1981
MB,BS University of London 1984
PhD University of London 1993

GMC registration

Reference number 2930794

Professional bodies (positions held - last 3 yrs)

College Tutor Royal College of Physicinas London 2007

Details of entry to specialist register

Haematology , 1993

Affiliations / memberships

UK Myeloma Forum (Executive Committee)

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)

HCA Healthcare UK at University College Hospital (5-50)
AB010
Leukapheresis (extraction of patient's cells) in connection with autologous Car-T Therapy - (1-5)

HCA Healthcare UK at University College Hospital (1-5)
AB013
Lymphodepletion and Infusion of T-cells in connection with autologous Car-T Therapy - (1-5)

HCA Healthcare UK at University College Hospital (1-5)
AB012
Haematologist delivery in connection with autologous CAR-T Therapy - (1-5)

HCA Healthcare UK at University College Hospital (1-5)

Report this page Print page

Finder

Note: